Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review

George V. Papatheodoridis, Pietro Lampertico, Spilios Manolakopoulos, Anna Lok

Research output: Contribution to journalArticle

293 Citations (Scopus)

Abstract

Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. Methods: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for ≥24 months. Results: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p = 0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p

Original languageEnglish
Pages (from-to)348-356
Number of pages9
JournalJournal of Hepatology
Volume53
Issue number2
DOIs
Publication statusPublished - Aug 2010

Fingerprint

Chronic Hepatitis B
Hepatocellular Carcinoma
Incidence
Therapeutics
Fibrosis
Cohort Studies

Keywords

  • Antivirals
  • Hepatitis B
  • Hepatocellular carcinoma
  • Lamivudine
  • Nucleoside analogues
  • Nucleotide analogues

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy : A systematic review. / Papatheodoridis, George V.; Lampertico, Pietro; Manolakopoulos, Spilios; Lok, Anna.

In: Journal of Hepatology, Vol. 53, No. 2, 08.2010, p. 348-356.

Research output: Contribution to journalArticle

Papatheodoridis, George V. ; Lampertico, Pietro ; Manolakopoulos, Spilios ; Lok, Anna. / Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy : A systematic review. In: Journal of Hepatology. 2010 ; Vol. 53, No. 2. pp. 348-356.
@article{5bcb8e1d2ce14e7eb71b2f9d220abf72,
title = "Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review",
abstract = "Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. Methods: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for ≥24 months. Results: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8{\%} and 6.4{\%} of treated and untreated patients, respectively, during a 46 (32-108) month period (p = 0.003), in 10.8{\%} and 0.5{\%} of nucleos(t)ide naive patients with and without cirrhosis (p",
keywords = "Antivirals, Hepatitis B, Hepatocellular carcinoma, Lamivudine, Nucleoside analogues, Nucleotide analogues",
author = "Papatheodoridis, {George V.} and Pietro Lampertico and Spilios Manolakopoulos and Anna Lok",
year = "2010",
month = "8",
doi = "10.1016/j.jhep.2010.02.035",
language = "English",
volume = "53",
pages = "348--356",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy

T2 - A systematic review

AU - Papatheodoridis, George V.

AU - Lampertico, Pietro

AU - Manolakopoulos, Spilios

AU - Lok, Anna

PY - 2010/8

Y1 - 2010/8

N2 - Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. Methods: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for ≥24 months. Results: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p = 0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p

AB - Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC incidence from studies in chronic hepatitis B patients treated with nucleos(t)ide analogues. Methods: We performed a literature search to identify studies with chronic hepatitis B patients treated with nucleos(t)ide analogues for ≥24 months. Results: Twenty-one studies including 3881 treated and 534 untreated patients met our inclusion criteria. HCC was diagnosed in 2.8% and 6.4% of treated and untreated patients, respectively, during a 46 (32-108) month period (p = 0.003), in 10.8% and 0.5% of nucleos(t)ide naive patients with and without cirrhosis (p

KW - Antivirals

KW - Hepatitis B

KW - Hepatocellular carcinoma

KW - Lamivudine

KW - Nucleoside analogues

KW - Nucleotide analogues

UR - http://www.scopus.com/inward/record.url?scp=77955306935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955306935&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2010.02.035

DO - 10.1016/j.jhep.2010.02.035

M3 - Article

C2 - 20483498

AN - SCOPUS:77955306935

VL - 53

SP - 348

EP - 356

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -